113. Muscular dystrophy Clinical trials / Disease details


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000692-32-IT
(EUCTR)
17/07/201914/01/2020Trial to evaluate the efficacy of the drug metformin on the muscles in patients with myotonic distrophy type 1 EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial. - MetMyd Myotonic Distrophy type 1, confirmed by genetic testing, with a CTG expansion size >100
MedDRA version: 20.0;Level: PT;Classification code 10068871;Term: Myotonic dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10013987;Term: Dystrophia myotonica;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: METFORMINA - 500 30 COMPRESSE 500 MG
Product Name: Metformina
INN or Proposed INN: Metformina
DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATANULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
194 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noItaly
2NCT01995032
(ClinicalTrials.gov)
October 201320/11/2013L-citrulline and Metformin in Duchenne's Muscular DystrophyA Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular DystrophyDuchenne's Muscular Dystrophy (DMD)Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.;Drug: PlaceboUniversity Hospital, Basel, SwitzerlandNULLCompleted78 Months10 YearsAll47Phase 3Switzerland
3EUCTR2013-001732-21-FR
(EUCTR)
06/09/201318/02/2014A phase II study of metformin in myotonic dystrophy type 1 patientsA randomized, double blind, placebo-controlled phase II study of metformin in myotonic dystrophy type 1 patients - Myomet Myotonic dystrophy type 1 (DM1) also known as Steinert disease;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: metformin 500mg
INN or Proposed INN: METFORMIN
Centre d'Etude des Cellules Souches (CECS)NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France
4NCT02018731
(ClinicalTrials.gov)
June 201317/12/2013L-citrulline and Metformin in Becker's Muscular DystrophyPilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular DystrophyBecker's Muscular Dystrophy (BMD)Drug: Metformin and Metformin & L-Citrulline;Drug: L-Citrulline and Metformin & L-CitrullineUniversity Hospital, Basel, SwitzerlandNULLCompleted18 YearsN/ABoth20Phase 2Switzerland
5NCT02516085
(ClinicalTrials.gov)
January 20123/8/2015Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and MetforminDuchenne Muscular DystrophyDrug: Metformin;Drug: L-ArginineUniversity Hospital, Basel, SwitzerlandNULLCompleted7 Years10 YearsBoth5Phase 1NULL